-
CTN 119: Abacavir plus Amprenavir versus Nelfinavir
A Comparison of a Four-drug Regimen Comprised of 141W94, Abacavir (1592U89), and Combivir with a Three-drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naïve, HIV-Infected Subjects. (Protocol 528/270 [NZTA4002])
-
CTN 118: Once Daily ADV plus ddI plus 3TC plus NVP (QD Study)
A Comparative Study of the Antiviral Effect of a Two or Three Times Daily Triple-Drug Regimen (Indinavir, Nelfinavir or Saquinavir [SGC], Lamivudine plus Zidovudine or Stavudine) against a Once Daily Regimen including Adefovir, Didanosine, Lamivudine and Nevirapine: Trial results
-
CTN 117: Intermittent Rifabutin for MAC and TB
A Pharmacokinetic Assessment of Intermittent Rifabutin Dosing Regimens in the Setting of Protease Inhibitor Therapy with a Combination of Ritonavir and Saquinavir in HIV-Infected Patients: Trial results
-
CTN 115: 141W94 (Amprenavir) versus Indinavir
A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Standard Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI-Experienced, Protease Inhibitor (PI)-Naïve, HIV-1 Infected Patients. (Protocol PROA/B3006 [569/050]): Trial results
-
CTN 114: SCH 56592 versus Fluconazole for Thrush
A Multicentre, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients: Trial results
-
CTN 113: Adding 1592 (Abacavir) versus Adding Indinavir
A Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IND in HIV-1 Infected, Antiretroviral Therapy-Naïve Subjects: Trial results
-
CTN 112: DMP 266 plus Indinavir
A Phase III, Double-Blind, Placebo-Controlled, Multicentre Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy: Trial results
-
CTN 111: DMP 266 (Efavirenz) in Two- or Three-Drug Arm
A Phase III, Multicentre, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Combination Regimens (DMP 266 plus Indinavir, DMP 266 plus Zidovudine plus Lamivudine, Indinavir plus Zidovudine plus Lamivudine) in HIV-Infected Patients
-
CTN 110: Subcutaneous interleukin-2 in the setting of HIV infection
A randomized, open-label, phase III, international study of subcutaneous recombinant IL-2 (Proleukin®) in patients with HIV-1 infection and CD4+ cell counts u0026gt; 300 cells/mm3 (Evaluation of subcutaneous Proleukin in a randomized international trial; ESPRIT): Trial results
-
CTN 102: Nelfinavir versus Ritonavir (NvR)
A Randomized Trial of the Efficacy and Safety of Nelfinavir vs. Ritonavir added to Background Antiretroviral Nucleoside Therapy in HIV-Infected Individuals with CD4+ Cell Counts u0026lt; 100 mm3: Trial results
-
CTN 101: Hydrea in Combination
A randomized study of antiviral activity and safety of combinations of didanosine, stavudine, zidovudine, and/or hydrea in anti-retroviral treatment-naive HIV-infected subjects: Trial results
-
CTN 094: AZT/3TC/Nelfinavir (AVANTI III)
A Randomized, Double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection. (AVANTI-Project 113; Protocol 067C): Trial results
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.v
Learn More